Skip to content

Vascular Response to Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in patients with Diabetes Mellitus

Vascular Response to Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in patients with Diabetes Mellitus - BVS-DM First

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38428
Enrollment
50
Registered
2014-01-14
Start date
2013-12-01
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angina pectoris coronary sclerosis

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patient is at least 18 years of age. 2. Patient is know with diabetes mellitus 3. Patient presenting with NSTEMI, stable or unstable angina , or silent ischemia caused by a de novo stenotic lesion in a native previous untreated coronary artery 4. Dmax (proximal and distal mean lumen diameter) within the upper limit of 3.8 mm and the lower limit of 2.0 mm by online QCA (at the moment only for the 2.5 mm and 3.5 mm devices) 5. The patient understands and accepts the meaning and the aims of the study 6. The patient is willing to comply with specified follow-up evaluation and can be contacted by telephone (Signed Informed Consent)

Exclusion criteria

Exclusion criteria: 1. Previous CABG 2. Cardiogenic shock 3. STEMI patients requiring immediate stent implantation 4. Bifurcation lesion requiring kissing balloon postdilatation 5. Allergies or contraindications to antiplatelet medication or contrast material 6. Female patient with child bearing potential not taking adequate contraceptives or currently breasfeeding 7. Expected survival of

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the evaluation of the scaffold coverage at 6-month follow-up by invasive coronary imaging with Optical Coherence Tomography.

Secondary

MeasureTime frame
Secondary objectives of the present investigation include OCT, QCA, NIRS imaging (baseline and 6 month) and clinical endpoints (until 5 years follow-up)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)